<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Human urotensin-II (UII) is a cyclic neuropeptide with potent vasoconstrictive activity in the vasculature </plain></SENT>
<SENT sid="1" pm="."><plain>The expression of UII and its receptor (UT) <z:chebi fb="2" ids="33699">mRNA</z:chebi> is detected at high levels in the brain </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the relationship between plasma UII levels and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) caused by <z:hpo ids='HP_0001297'>stroke</z:hpo> or atherosclerotic small vessel disease </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Carotid artery intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>), plaques, plasma levels of immunoreactive UII (IR-UII), and atherosclerotic biomarkers were determined in 42 patients with VaD, 197 with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), and 47 non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> elderly controls </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Age, gender, body mass index, systolic blood pressure (SBP), fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin, <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi>, leptin, and plasminogen activator inhibitor-1 levels were not significantly different among these groups </plain></SENT>
<SENT sid="5" pm="."><plain>IR-UII, <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) cholesterol, <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a), <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="39" ids="44785">peroxides</z:chebi>, interleukin-6, and high-sensitive C-reactive protein (hs-CRP) levels, and maximum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> were significantly higher in VaD than in AD patients or controls </plain></SENT>
<SENT sid="6" pm="."><plain>IR-UII level showed a significantly positive correlation with SBP or maximum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Multivariate logistic regression analysis revealed a significantly independent association between IR-UII levels or increased maximum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> (&gt; or =1.1 mm) and VaD as compared with SBP, <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, and interleukin-6 levels </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Increased plasma IR-UII levels and carotid <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> may be involved in the pathogenesis and progression of VaD </plain></SENT>
</text></document>